Sign in
CompletedNo phase

Association Between Matrix Metalloproteinase-2 Gene Polymorphism rs243865 and Susceptibility to Cataract Development

Key facts

Who runs it
Sohag University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
90 people enrolled
Started
1 Jul 2023
Ended
30 Apr 2024
Type of study
Observational, 3 groups
Treatments tested
  • genotyping assay by real-time PCR
  • ELISA
Record updated
23 July 2024

Who can take part

Age
21 years and older
Sex
Women and men

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Group A (control group) will include 30 eyes of 30 normal healthy non-cataractous volunteers aged ≥21 years. Group B (experimental group 1) will include 30 eyes of 30 cataractous patients aged >50 years and diagnosed with senile cataract. Group C (experimental group 2) will include 30 eyes of 30 cataractous patients aged ≥21 to 50 years and diagnosed with secondary cataract. The control group will include participants who will be age-matched and sex-matched with the patients in the experimental groups

Who cannot take part

  • concomitant eye pathology or inflammation, systemic diseases and previous eye or systemic surgery

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary aim of this study is to investigate the potential association between MMP-2 gene polymorphism and susceptibility to cataract development in Egyptian patients. Furthermore, this study aims to compare between cataract patients and healthy controls by measuring the serum IL-6 concentration to evaluate its relationship with disease.

The 3 groups in the trial

  • control group (GroupA)

    normal healthy non-cataractous volunteers aged ≥21 years

    Treatment: genotyping assay by real-time PCR and ELISA

  • Group B (experimental group 1)

    cataractous patients aged \>50 years and diagnosed with senile cataract.

    Treatment: genotyping assay by real-time PCR and ELISA

  • Group C (experimental group 2)

    cataractous patients aged ≥21 to 50 years and diagnosed with secondary cataract

    Treatment: genotyping assay by real-time PCR and ELISA

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
23 July 2024